Stock 002821 ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Asymchem Laboratories (Tianjin) Co., Ltd. Stock

Equities

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
82.65 CNY -1.82% Intraday chart for Asymchem Laboratories (Tianjin) Co., Ltd. +2.05% -28.81%
Apr. 29 Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3% MT
Apr. 26 Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT

Financials

Sales 2024 * 6.45B 890M Sales 2025 * 7.73B 1.07B Capitalization 28.88B 3.99B
Net income 2024 * 1.25B 172M Net income 2025 * 1.73B 239M EV / Sales 2024 * 3.5 x
Net cash position 2024 * 6.29B 869M Net cash position 2025 * 8.09B 1.12B EV / Sales 2025 * 2.69 x
P/E ratio 2024 *
24.9 x
P/E ratio 2025 *
17.5 x
Employees 9,788
Yield 2024 *
0.83%
Yield 2025 *
1.02%
Free-Float 60.56%
More Fundamentals * Assessed data

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Dynamic Chart

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3% MT
Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024. CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023 MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023 CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Asymchem Laboratories Completes A-Share Repurchase Program MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024. CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024 CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback MT
More news

Analyst Recommendations on Asymchem Laboratories (Tianjin) Co., Ltd.

Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$134.59 From HK$130.30, Keeps at Buy MT
More recommendations

Press releases Asymchem Laboratories (Tianjin) Co., Ltd.

AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor AQ
Asymchem Laboratories Tianjin : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section PU
Asymchem Laboratories Tianjin : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section PU
AzurRx BioPharma : Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production AQ
More press releases

News in other languages on Asymchem Laboratories (Tianjin) Co., Ltd.

# Morning note : economia e finanza dai giornali
El crudo se recupera y sube un 2% apoyado en menor ansiedad por COVID en China
Borsa: Hong Kong chiude a +5,23%, voci di stop a zero-Covid
Spekulationen über Lockerung der Corona-Maßnahmen in China
Cina : il mondo a caccia di indizi su stato salute economia Pechino
More news

Quotes and Performance

1 day-1.82%
1 week+2.05%
1 month-2.87%
3 months-3.58%
6 months-43.97%
Current year-28.81%
More quotes

Highs and lows

1 week
81.40
Extreme 81.4
84.83
1 month
74.91
Extreme 74.91
84.83
Current year
74.91
Extreme 74.91
116.22
1 year
74.91
Extreme 74.91
165.27
3 years
74.91
Extreme 74.91
380.35
5 years
59.54
Extreme 59.5357
380.35
10 years
13.09
Extreme 13.0857
380.35
More quotes

Managers and Directors - Asymchem Laboratories (Tianjin) Co., Ltd.

Managers TitleAgeSince
Rui Yang CEO
 Chief Executive Officer 47 99-03-31
Hao Hong CEO
 Chief Executive Officer 68 98-10-06
Elut Hsu PSD
 President - 96-12-31
Members of the board TitleAgeSince
Hao Hong CEO
 Chief Executive Officer 68 98-10-06
Rui Yang CEO
 Chief Executive Officer 47 99-03-31
Xin Yi Hou BRD
 Director/Board Member 64 Feb. 28
More insiders

ETFs positioned on Asymchem Laboratories (Tianjin) Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.88% 2 M€ -12.62% -
More ETFs positioned on Asymchem Laboratories (Tianjin) Co., Ltd.

Quotes

Date Price Change Volume
24-04-30 82.65 -1.82% 4,022,745
24-04-29 84.18 +3.94% 6,985,970
24-04-26 80.99 +5.37% 8,041,430
24-04-25 76.86 -0.59% 4,461,081

End-of-day quote Shenzhen S.E., April 29, 2024

More quotes

Company Profile

Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.
Sector
Pharmaceuticals
Calendar
2024-08-14 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
82.65 CNY
Average target price
99.42 CNY
Spread / Average Target
+20.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. Stock Asymchem Laboratories (Tianjin) Co., Ltd.
-28.81% 3.99B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002821 Stock